Special Issue

Novel Strategies for Cancer Targeted Delivery

Message from the Guest Editors

Among the controlled drug delivery technologies, targeted drug delivery has attracted the attention of researchers, as it comprises the systemic delivery of a drug carrier system to specific cell types, tissues, or organs. Targeted drug delivery systems would mainly be beneficial in diseases such as cancers, which are a leading cause of death worldwide. Advancements in omic sciences, analytical procedures, and highthroughput screening in the last two decades have led to the realization that cancer is more complex than was originally conceived. Numerous challenges impede effective cancer treatment and development of effective drugs such as ineffective therapeutic drug concentrations reaching the tumor site, life-threatening side effects caused by nonspecific tissue distribution of anti-neoplastic agents, and acquired resistance of cancer cells upon chemotherapy that triggers crossresistance to a wide range of different drugs. The complexity of cancers requires the development of very delicate approaches in the course of the drug discovery pipeline.

Guest Editors

Dr. Magdalena Markowicz-Piasecka

Department of Pharmaceutical Chemistry, Drug Analysis and radiopharmacy, Medical University of Lodz, 90-151 Lodz, Poland

Dr. Kristiina Huttunen

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O.Box 1627, Fl-70211 Kuopio, Finland

Deadline for manuscript submissions

closed (31 August 2022)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/96645

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

